Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer got a reprieve in late January when Starboard didn’t nominate its own slate of directors to the company’s board, but the activist could still agitate for changes in 2026.

According to Starboard Value LP, Pfizer Inc. (NYSE:PFE) has erased more than $20 billion in market value since 2019 despite receiving $40 billion from the sale of Covid 19 vaccines.

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency even as it reported lower ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

To put Pfizer's deal in perspective, rival Merck & Co. Inc. (MRK) had announced in November 2024 a licensing deal with Shanghai-based LaNova Medicines Ltd. for PD-1/VEGF antibody LM-299, in which ...